Bausch Health Companies Inc. (BHC)

Eye care and pharmaceutical plants and sales forces. Read October 19, 2026 from the annual report for the period ending December 31, 2025, filed February 19, 2026. Ranked 25 of the 47 Healthcare companies read so far, by the share within reach now.

A health company whose filing counts employees by function, by region and by its Bausch + Lomb subsidiary, so the pharmaceutical and device patterns follow those counts with the administrative count under rule 6.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 19% now, 34% at the end of 2027, 41% at the end of 2028, 44% at the end of 2030. By the patterns, the work is about 44% desk work, 15% people work and 41% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 55% of the working time stays with people (conversation, in-person and hands-on work), 37% becomes checking a model's work and 5% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

20,300 employees as of December 31, 2025 (stated). The filing counts the United States and Canada together, about 7,700 of 20,300 (38%); 62% of 2025 revenue was in the United States and Puerto Rico.

The filing: “As of December 31, 2025, we had approximately 20,300 employees, of which approximately 13,000 were Bausch + Lomb employees.”

The workforce as industry patterns

What the filing says about the workforce: About 20,300 employees, 13,000 of them Bausch + Lomb: 10,300 in production, 6,800 in sales and marketing, 1,800 in general and administrative positions, 1,400 in research and development; about 7,700 in the United States and Canada, 7,100 in Europe, 2,550 in Asia-Pacific, 2,200 in Latin America, 450 in Russia; some employees are under collective bargaining, trade union or works council agreements.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Johnson & Johnson (JNJ, 140,800 employees)19% now, 39% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)20% now, 49% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)19% now, 41% by 2028
• Pfizer Inc. (PFE, 75,000 employees)19% now, 41% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)19% now, 41% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)19% now, 41% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)19% now, 41% by 2028
• Amgen Inc. (AMGN, 31,500 employees)19% now, 41% by 2028

What the filing says about AI

20 sentences in the filing name AI. The filing says it uses proprietary and third-party AI in various aspects of its business and operations and may continue to, and treats that use as a risk that could expose it to liability.

• “Some of the risks we face include: the impact of the current market and macroeconomic conditions in one or more of our markets on our business; the impact on our business relating to the B+L IPO and the B+L Separation, including the uncertainties with respect to the expected timing of completion of the B+L Separation; the impact of ongoing and potential legal proceedings, investigations and inq...”
• “We utilize artificial intelligence, which could expose us to liability or could have a material adverse effect on our business and financial condition.”
• “We utilize proprietary and third party artificial intelligence ("AI") in various aspects of our business and operations, and may continue to do so in the future.”
• “There may be significant risks involved in utilizing AI and no assurance can be provided that our use will enhance our business and operations or produce the intended results.”
• “For example, AI algorithms may be flawed, insufficient, of poor quality, reflect unwanted forms of bias, or contain other errors or inadequacies, any of which may not be easily detectable.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20230median 1
• Fiscal 202411median 4
• Fiscal 202520median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The U.S. share is not stated; the filing counts the United States and Canada together.
• Pattern shares rest on the stated Bausch + Lomb and administrative counts (a) with the product split by description (c); the function counts do not split by product.
• The filing describes a planned separation of Bausch + Lomb, recorded as it states it.

Source: the company's annual report on EDGAR, accession 0000885590-26-000023, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.